Sequential GO, chemotherapy no benefit for older AML patients according trial
Tuesday, October 22, 2013 - 11:30
in Health & Medicine
Results of a randomized, phase III, trial show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.